ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO650

Development of a Radiomic-Clinical Nomogram to Predict the Treatment Resistance of Myeloperoxidase ANCA-Associated Vasculitis

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Yong, Zhong, Xiangya Hospital Central South University, Changsha, Hunan, China

We aimed to develop a radiomics nomogram to predict the treatment resistance of MPO-AAV patients.


MPO-AAV patients were randomly assigned to a training cohort and a test cohort. Treatment-resistance related features were selected using multivariate logistic regression to obtained the radiomic score (Rad-score). Two models were built. The clinical utility of the good models was assessed by decision curve analysis (DCA). The calibration of combined radiomics nomogram was evaluated.


Serum creatinine and 9 radiomics features were selected, which were related to the treatment resistance of MPO-AAV. The accuracy of Model 2 (radiomics nomogram) for the prediction of treatment resistance was 0.948 and 0.913 in the training and test cohorts, which was higher than Model 1 (radiomics) with the AUC of 0.824 (p=0.039), and 0.898 (p=0.043) respectively. The DCA curve demonstrated that Model 2 had a higher net clinical benefit than that of Models 1. The calibration curves of Model 2 closely aligned with the true treatment resistance rate in the training (p =0.28) and validation sets (p =0.70). Furthermore, the validation cohort gained a good AUC of 0.929 in the Model 2.


The radiomics nomogram is a useful for predicting the treatment resistance of MPO-AAV.